Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010937
Filing Date
2025-05-15
Accepted
2025-05-15 16:15:59
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1561679
2 EX-31.1 ex31-1.htm EX-31.1 19021
3 EX-31.2 ex31-2.htm EX-31.2 19239
4 EX-32.1 ex32-1.htm EX-32.1 7531
5 EX-32.2 ex32-2.htm EX-32.2 7497
  Complete submission text file 0001641172-25-010937.txt   8210417

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mymd-20250331.xsd EX-101.SCH 60601
7 XBRL CALCULATION FILE mymd-20250331_cal.xml EX-101.CAL 50204
8 XBRL DEFINITION FILE mymd-20250331_def.xml EX-101.DEF 286325
9 XBRL LABEL FILE mymd-20250331_lab.xml EX-101.LAB 531465
10 XBRL PRESENTATION FILE mymd-20250331_pre.xml EX-101.PRE 414434
70 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1374031
Mailing Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 25953399
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)